RxDoctor Payments Data

Ravneet Singh, MD

Child & Adolescent Psychiatry · Chicago, ILNPI 1265053771

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 38.5% of the total. 2025 is the largest year on record at $1,246, more than ten times the $18 reported in 2022.

$1,590in general payments, 2019–2025

Across 67 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$613
  • Johnson & Johnson$448
  • Teva Pharmaceuticals USA, Inc.$126
  • Axsome Therapeutics, Inc.$84
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$70
  • Lundbeck LLC$67
  • plus $183 from 6 others

What the payments were for

  • Food & beverage$1,590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,590 in reported general payments places this provider in the 80th percentile of 124 child & adolescent psychiatry providers in Illinois.

See all child & adolescent psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$50,951
Medicare patients
103
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$63,835
Divalproex Sodium28$677
Fluphenazine Hcl11$433
Quetiapine Fumarate41$396
Lorazepam39$359
Olanzapine43$328
Mirtazapine13$242
Haloperidol11$229
Venlafaxine Hcl ErVenlafaxine Hcl14$228
Lamotrigine27$218
Gabapentin32$218
Risperidone40$205
Trazodone Hcl24$171
Clonazepam47$160
Buspirone Hcl14$138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$448$63,83520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 124 child & adolescent psychiatry providers in Illinois.

Other child & adolescent psychiatry in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →